Evaxion A EVAX
NASDAQ EVAX
$3.20 +0.02 (+0.63%)
At close: Oct 2, 2026 · 4:00 PM EDT

Evaxion A (EVAX) Price to Sales (2024 - 2026)

Updated

Evaxion A's Price to Sales came in at 2.65 for Q2 2026, up 220.4% from 0.83 a year earlier but down 16.3% from the prior quarter.

Analysis

Evaxion A (EVAX) Price to Sales (2024 - 2026) Analysis & Trends

For FY2025, Evaxion A's Price to Sales was 4.06, up 199.9% from FY2024.

  • Going back by year, Price to Sales was 1.35 in FY2024 (-99.5%) and 256.88 in FY2023.
  • The five-year range for quarterly Price to Sales is 0.53 (Q3 2025) to 4.06 (Q4 2025).
  • Year-over-year, Price to Sales has increased for three consecutive quarters, with growth averaging 191.4% over the last four quarters.
  • Business Quant data shows EVAX's Price to Sales at 3.17 (Q1 2026), 4.06 (Q4 2025) and 0.53 (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn
10 Evaxion A 20.38 Mn -45.87 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.65
Mar 31, 2026 3.17
Dec 31, 2025 4.06
Sep 30, 2025 0.53
Jun 30, 2025 0.83
Mar 31, 2025 0.60
Dec 31, 2024 1.35
Sep 30, 2024 2.64
API Access

Evaxion A Price to Sales API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=price-to-sales&ticker=EVAX&period=max&api_key=YOUR_API_KEY